Patrick Machado
CIK 1311210 · Chief Business Officer and CFO · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.35M
Companies
16
Total Filings
139
Lifetime Open-Market Net
$27.09M
Filer Profile
Reported Address
201 SPEAR STREET, 3RD FLOORSAN FRANCISCO, CA 94107
Formerly Known As
Machado Clarence Patrick (2004–2016)
Related Filers
Roivant Sciences Ltd. — 1 joint filings, latest 2021-10-01
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALMS | Director | 10,617 | $9.18 | $97.5K | $0 | 4 | 2026-07-02 |
| RCUS | Director | 44,300 | $24.59 | $1.09M | $0 | 8 | 2026-06-12 |
| XENE | Director | 2,645 | $58.65 | $155.1K | $0 | 7 | 2026-06-03 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | Director | 0 | $4.36 | $0 | $214.4K | 15 | 2025-12-10 |
| ACELYRIN, Inc. (SLRN) Delisted | Director | 14,675 | $2.27 | $33.3K | $0 | 3 | 2024-06-11 |
| CHIMERIX INC (CMRX) Delisted | Director | 10,000 | $8.54 | $85.4K | $70.8K | 10 | 2023-06-12 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | — | $76.01 | — | $0 | 4 | 2022-08-17 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | — | — | — | $0 | 3 | 2020-09-28 |
| Urovant Sciences Ltd. (UROV) Delisted | 10%+ Owner | 22,860,013 | $16.24 | $371.25M | $38.75M | 9 | 2019-06-19 |
| Myovant Sciences Ltd. (MYOV) Delisted | 10%+ Owner | 40,765,599 | $26.98 | $1.10B | $42.50M | 2 | 2019-06-06 |
| SCYX | Director | 750 | $4.84 | $3.6K | $165.4K | 7 | 2019-01-04 |
| ENDOCYTE INC (ECYT) Delisted | Director | 0 | — | — | $0 | 3 | 2018-12-21 |
| ABUS | 10%+ Owner | — | $5.12 | — | $0 | 2 | 2018-01-16 |
| ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted | Director | — | — | — | $0 | 2 | 2017-06-21 |
| MEDIVATION, INC. (MDVN) Delisted | Director | 219,564 | — | — | -$54.43M | 52 | 2016-06-23 |
| MEDIVATION, INC. (MDV) Delisted | Sr. Vice President and CFO | 486,123 | $18.05 | $8.77M | -$178.0K | 1 | 2007-03-20 |
Recent Filings · Page 9 of 14
139 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-06-28 | SCYX | Buy (P) | +20,000 | $47.8K | EDGAR |
| 2016-06-28 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-23 | MEDIVATION, INC. (MDVN) Delisted | Grant (A) | +2,972 | $0 | EDGAR |
| 2016-06-06 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2016-01-21 | MEDIVATION, INC. (MDVN) Delisted | Mixed | — | -$2.55M | EDGAR |
| 2015-12-30 | CHIMERIX INC (CMRX) Delisted | Buy (P) | +10,000 | $70.8K | EDGAR |
| 2015-09-28 | MEDIVATION, INC. (MDVN) Delisted | Mixed | — | -$2.71M | EDGAR |
| 2015-09-28 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2015-06-24 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-18 | MEDIVATION, INC. (MDVN) Delisted | Grant (A) | +1,578 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.